Japanese guidelines for adult asthma 2020

Bronchial asthma is characterized by chronic airway inflammation, which manifests clinically as variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma may induce airway remodeling and become intractable. The prevalence of asthma has increased; however, the number of patients...

Full description

Bibliographic Details
Main Authors: Yoichi Nakamura, Jun Tamaoki, Hiroyuki Nagase, Masao Yamaguchi, Takahiko Horiguchi, Soichiro Hozawa, Masakazu Ichinose, Takashi Iwanaga, Rieko Kondo, Makoto Nagata, Akihito Yokoyama, Yuji Tohda
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Allergology International
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893020301015
id doaj-20782b60fcac4375b20221d20b4ca0a7
record_format Article
spelling doaj-20782b60fcac4375b20221d20b4ca0a72020-11-25T02:48:21ZengElsevierAllergology International1323-89302020-10-01694519548Japanese guidelines for adult asthma 2020Yoichi Nakamura0Jun Tamaoki1Hiroyuki Nagase2Masao Yamaguchi3Takahiko Horiguchi4Soichiro Hozawa5Masakazu Ichinose6Takashi Iwanaga7Rieko Kondo8Makoto Nagata9Akihito Yokoyama10Yuji Tohda11Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital, Yokohama, Japan; Corresponding author. Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital, 3-12-1 Shin-Yamashita, Naka-ku, Yokohama, Kanagawa 231-8682, Japan.First Department of Medicine, Tokyo Women's Medical University, Tokyo, JapanDivision of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, JapanThird Department of Medicine, Teikyo University Chiba Medical Center, Chiba, JapanDepartment of Respiratory Medicine, Fujita Health University Bantane Hospital, Nagoya, JapanHiroshima Allergy and Respiratory Clinic, Hiroshima, JapanDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, JapanDepartment of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine, Osaka, JapanDepartment of Respiratory Medicine, Fujita Health University Bantane Hospital, Nagoya, JapanDepartment of Respiratory Medicine, Saitama Medical University Hospital, Saitama, JapanDepartment of Hematology and Respiratory Medicine, Kochi University, Kochi, JapanDepartment of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine, Osaka, JapanBronchial asthma is characterized by chronic airway inflammation, which manifests clinically as variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma may induce airway remodeling and become intractable. The prevalence of asthma has increased; however, the number of patients who die from it has decreased (1.3 per 100,000 patients in 2018). The goal of asthma treatment is to control symptoms and prevent future risks. A good partnership between physicians and patients is indispensable for effective treatment. Long-term management with therapeutic agents and the elimination of the triggers and risk factors of asthma are fundamental to its treatment. Asthma is managed by four steps of pharmacotherapy, ranging from mild to intensive treatments, depending on the severity of disease; each step includes an appropriate daily dose of an inhaled corticosteroid, which may vary from low to high. Long-acting β2-agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonists are recommended as add-on drugs, while anti-immunoglobulin E antibodies and other biologics, and oral steroids are reserved for very severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled β2-agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by selecting treatment steps for asthma based on the severity of the exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-exacerbated respiratory disease, and pregnancy are also important conditions to be considered in asthma therapy.http://www.sciencedirect.com/science/article/pii/S1323893020301015Definition of asthmaDiagnosis of asthmaEpidemiology of asthmaLong-term management of asthmaManagement of asthma exacerbation
collection DOAJ
language English
format Article
sources DOAJ
author Yoichi Nakamura
Jun Tamaoki
Hiroyuki Nagase
Masao Yamaguchi
Takahiko Horiguchi
Soichiro Hozawa
Masakazu Ichinose
Takashi Iwanaga
Rieko Kondo
Makoto Nagata
Akihito Yokoyama
Yuji Tohda
spellingShingle Yoichi Nakamura
Jun Tamaoki
Hiroyuki Nagase
Masao Yamaguchi
Takahiko Horiguchi
Soichiro Hozawa
Masakazu Ichinose
Takashi Iwanaga
Rieko Kondo
Makoto Nagata
Akihito Yokoyama
Yuji Tohda
Japanese guidelines for adult asthma 2020
Allergology International
Definition of asthma
Diagnosis of asthma
Epidemiology of asthma
Long-term management of asthma
Management of asthma exacerbation
author_facet Yoichi Nakamura
Jun Tamaoki
Hiroyuki Nagase
Masao Yamaguchi
Takahiko Horiguchi
Soichiro Hozawa
Masakazu Ichinose
Takashi Iwanaga
Rieko Kondo
Makoto Nagata
Akihito Yokoyama
Yuji Tohda
author_sort Yoichi Nakamura
title Japanese guidelines for adult asthma 2020
title_short Japanese guidelines for adult asthma 2020
title_full Japanese guidelines for adult asthma 2020
title_fullStr Japanese guidelines for adult asthma 2020
title_full_unstemmed Japanese guidelines for adult asthma 2020
title_sort japanese guidelines for adult asthma 2020
publisher Elsevier
series Allergology International
issn 1323-8930
publishDate 2020-10-01
description Bronchial asthma is characterized by chronic airway inflammation, which manifests clinically as variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma may induce airway remodeling and become intractable. The prevalence of asthma has increased; however, the number of patients who die from it has decreased (1.3 per 100,000 patients in 2018). The goal of asthma treatment is to control symptoms and prevent future risks. A good partnership between physicians and patients is indispensable for effective treatment. Long-term management with therapeutic agents and the elimination of the triggers and risk factors of asthma are fundamental to its treatment. Asthma is managed by four steps of pharmacotherapy, ranging from mild to intensive treatments, depending on the severity of disease; each step includes an appropriate daily dose of an inhaled corticosteroid, which may vary from low to high. Long-acting β2-agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonists are recommended as add-on drugs, while anti-immunoglobulin E antibodies and other biologics, and oral steroids are reserved for very severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled β2-agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by selecting treatment steps for asthma based on the severity of the exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-exacerbated respiratory disease, and pregnancy are also important conditions to be considered in asthma therapy.
topic Definition of asthma
Diagnosis of asthma
Epidemiology of asthma
Long-term management of asthma
Management of asthma exacerbation
url http://www.sciencedirect.com/science/article/pii/S1323893020301015
work_keys_str_mv AT yoichinakamura japaneseguidelinesforadultasthma2020
AT juntamaoki japaneseguidelinesforadultasthma2020
AT hiroyukinagase japaneseguidelinesforadultasthma2020
AT masaoyamaguchi japaneseguidelinesforadultasthma2020
AT takahikohoriguchi japaneseguidelinesforadultasthma2020
AT soichirohozawa japaneseguidelinesforadultasthma2020
AT masakazuichinose japaneseguidelinesforadultasthma2020
AT takashiiwanaga japaneseguidelinesforadultasthma2020
AT riekokondo japaneseguidelinesforadultasthma2020
AT makotonagata japaneseguidelinesforadultasthma2020
AT akihitoyokoyama japaneseguidelinesforadultasthma2020
AT yujitohda japaneseguidelinesforadultasthma2020
_version_ 1724748311587454976